These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 21802835)

  • 1. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
    Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.
    Bjartell A
    Eur Urol; 2011 Nov; 60(5):905-7. PubMed ID: 21871707
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
    Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
    Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
    J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
    Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
    J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
    Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
    Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells.
    Mao X; Shaw G; James SY; Purkis P; Kudahetti SC; Tsigani T; Kia S; Young BD; Oliver RT; Berney D; Prowse DM; Lu YJ
    Asian J Androl; 2008 May; 10(3):467-73. PubMed ID: 18385909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
    Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR.
    Fernández-Serra A; Rubio L; Calatrava A; Rubio-Briones J; Salgado R; Gil-Benso R; Espinet B; García-Casado Z; López-Guerrero JA
    Biomed Res Int; 2013; 2013():465179. PubMed ID: 23781502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
    Lorente D; Olmos D; Mateo J; Bianchini D; Seed G; Fleisher M; Danila DC; Flohr P; Crespo M; Figueiredo I; Miranda S; Baeten K; Molina A; Kheoh T; McCormack R; Terstappen LW; Scher HI; de Bono JS
    Eur Urol; 2016 Dec; 70(6):985-992. PubMed ID: 27289566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
    Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
    Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.